SCHEMBL6489800

SCHEMBL6489800

CCc1nc2ccc(Br)nc2n1Cc1ccc(O)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
DYRK1A Q13627 1/20 0.34
HTR6 P50406 1/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGES O14684 1/20 0.32
ALOX5AP P20292 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ESRRB O95718 1/20 0.32
ESR1 P03372 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490800 0.86 ALDH1A1 (0.38) KDM4EALDH1A1HPGDSMN1; SMN2DYRK1A
SCHEMBL6491571 0.83 KMT2A (0.38) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6499926 0.81 SMN1; SMN2 (0.38) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6504961 0.80 SMN1; SMN2 (0.41) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6494971 0.76 HPGD (0.38) HPGDALOX5APPDE2A
SCHEMBL27556253 0.74 CYP19A1 (0.36) LMNAKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL6301874 0.73 PPARG (0.43) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6298644 0.72 CDK9 (0.39) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL9319006 0.71 LMNA (0.47) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6298833 0.70 HDAC3 (0.43) LMNAKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A LMNA 2742/4885KDM4E 1599/4885ALDH1A1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.